On August 30, 2018 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, reported that its Chief Executive Officer, Philip Serlin, will present a company update at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, BioLineRx, AUG 30, 2018, View Source;p=RssLanding&cat=news&id=2365462 [SID1234529213]). The conference is being held on September 4-6, 2018 at the St. Regis Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BioLineRx presentation is scheduled to start at 9:35 a.m. EDT on Wednesday, September 5, 2018. A live audio webcast of the presentation will be available online on the Investor Page of the Company’s website. An archive of the event will also be available for those unable to listen live.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (View Source) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.